Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.

导出 OA

翻译打印收藏纠错

第一作者： Maurits F J M,Vissers

第一单位： Centre for Human Drug Research, Leiden, The Netherlands.

作者： Maurits F J M,Vissers ^[1] ; Jules A A C,Heuberger ^[2] ; Geert Jan,Groeneveld ^[1] ; Jerome,Oude Nijhuis ^[1] ; Peter Paul,De Deyn ^[2] ; Salah,Hadi ^[3] ; Jeffrey,Harris ^[3] ; Richard M,Tsai ^[4] ; Andres,Cruz-Herranz ^[5] ; Fen,Huang ^[6] ; Vincent,Tong ^[6] ; Rebecca,Erickson ^[6] ; Yuda,Zhu ^[6] ; Kimberly,Scearce-Levie ^[6] ; Jennifer,Hsiao-Nakamoto ^[6] ; Xinyan,Tang ^[6] ; Megan,Chang ^[6] ; Brian M,Fox ^[6] ; Anthony A,Estrada ^[6] ; Robert J,Pomponio ^[6] ; Miguel,Alonso-Alonso ^[6] ; Moshe,Zilberstein ^[6] ; Nazem,Atassi ^[7] ; Matthew D,Troyer ^[7] ; Carole,Ho ^[7]

作者单位： Centre for Human Drug Research, Leiden, The Netherlands. ^[1] Leiden University Medical Center, Leiden, The Netherlands. ^[2] Department of Neurology and Alzheimer Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. ^[3] Laboratory of Neurochemistry and Behavior, Department of Biomedical Sciences and Institute Born-Bunge, University of Antwerp, Antwerp, Belgium. ^[4] PRA Health Sciences, Groningen, The Netherlands. ^[5] Denali Therapeutics Inc., South San Francisco, California, USA. ^[6] Sanofi Genzyme, Cambridge, Massachusetts, USA. ^[7]

主题词阿尔茨海默病(Alzheimer Disease);肌萎缩侧索硬化(Amyotrophic Lateral Sclerosis);双盲法(Double-Blind Method);人类(Humans);白细胞, 单核(Leukocytes, Mononuclear);受体作用蛋白丝氨酸苏氨酸激酶类(Receptor-Interacting Protein Serine-Threonine Kinases)

DOI 10.1111/cts.13317

PMID 35649245

发布时间 2022-10-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交